Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2020-05-28 Regulatory Filings
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
불성실공시법인지정예고(공시불이행)
Regulatory Filings Classification · 95% confidence The document is a formal notice from a regulatory body (KRX/Konex) regarding a 'Notice of Designation as an Unfaithful Disclosure Corporation' due to a delay in disclosing a capital increase. This is a regulatory announcement concerning compliance and legal/regulatory status, which fits the 'Regulatory Filings' category as it does not represent a financial report, dividend, or management change.
2020-05-28 Korean
증권신고서(지분증권)
Regulatory Filings Classification · 99% confidence The document is a '증권신고서' (Securities Registration Statement) filed by Gencurix with the Financial Services Commission (FSC) in South Korea. It details the issuance of new shares, investment risks, financial status, and business outlook for the purpose of a public offering (IPO). In the context of US-style financial filings, this corresponds to a registration statement for securities, which is categorized under 'Regulatory Filings' (RNS) as it is a formal regulatory document that does not fit into the specific categories of annual reports, earnings releases, or proxy statements.
2020-05-27 Korean
특허권취득(자율공시)(표준 발현 유전자를 발굴하기 위한 유전자 발현 데이터처리, 분석방법)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure regarding the acquisition of a patent ('특허권 취득') by the company Gencurix. It details the patent name, content, and utilization plan. Since this is a specific corporate announcement regarding intellectual property that does not fit into financial reporting, dividend, or management change categories, it falls under the general regulatory filing category.
2020-05-12 Korean
기타주요경영사항(자율공시)(코스닥시장 상장예비심사 결과 접수)
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from Gencurix regarding the approval of its preliminary review for KOSDAQ market listing. It is a short, formal disclosure of a specific corporate event (listing progress) rather than a full financial report or a report publication announcement. As it pertains to general regulatory disclosure of corporate developments that do not fit into specific categories like M&A or share issues, it is classified as a Regulatory Filing (RNS).
2020-04-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (in this case, due to the resignation of an executive). This falls under the category of Major Shareholding Notification.
2020-04-01 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, etc.), the name of the auditor (Samil PwC), and the date of receipt. While it contains financial data, it is a standalone regulatory disclosure regarding the completion and submission of the audit report, which falls under the 'Audit Report / Information' category. FY 2019
2020-03-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.